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The 2008 ASH Annual Meeting featured several important
abstracts highlighting advances in the treatment of
chronic lymphocytic leukemia (CLL).
Abstract 43 [1] retrospectively compared results of a phase
II study of pentostatin and rituximab (PR) to previously
published results using pentostatin, cyclophosphamide
and rituximab (PCR) [2]. The pentostatin dose was
increased to 4 mg/m2 in the PR regimen, but demograph-
ics of patients in both studies were similar [1]. Overall
response rate (OR) and complete response (CR) rates
were similar for PR (79%, 30%) and PCR (91%, 41%),
but median progression free survival (PFS) was signifi-
cantly shorter for PR (12 months vs. 31 months) [1].
These results supported previous findings that the addi-
tion of cyclophosphamide to fludarabine improves OR,
CR and PFS [3-5].
Abstract 325 presented results of the German CLL Study
Group (GCLLSG) CLL8 study randomizing 817 previ-
ously untreated patients to fludarabine and cyclophos-
phamide (FC) or fludarabine, cyclophosphamide and
rituximab (FCR) [6]. OR, CR and median PFS favored FCR
(93%, 45%, 43 months) over FC (85%, 23%, 32 months),
although 2-year overall survival (OS) was similar (91% vs.
88%). Abstract 326 demonstrated that median PFS
depended upon the ability to eradicate minimal residual
disease (MRD) in the peripheral blood, with PFS increas-
ing from 15 months (MRD  10-2) to 34 months (10-4 
MRD >10-2) to not reached (MRD <10-4) with increasing
eradication of MRD [7]. Furthermore, 67% of patients
receiving FCR achieved MRD <10-4, compared to only
34% of FC patients, thus accounting for the improved PFS
with FCR.
Abstract 327 randomized 184 patients (80% previously
untreated, 20% relapsed) to PCR or FCR, using the
MSKCC PCR regimen (pentostatin dose 4 mg/m2) and the
Johns Hopkins FCR regimen (fludarabine 20 mg/m2 days
1–5, cyclophosphamide 600 mg/m2 day 1). The primary
endpoint, incidence of grade 3–4 infections, was similar
for PCR (34%) and FCR (31%). Only 50% of patients in
both arms completed therapy, resulting in surprisingly
low OR and CR rates for PCR (45%, 7%) and FCR (58%,
17%). The trial was stopped early, so there were no statis-
tically significant differences between the two arms, and
no PFS data was presented. Nonetheless, abstract 327
indicated that results from academic centers may not nec-
essarily be reproducible in the community [8].
Abstract 2095 updated results of a phase II study of cyclo-
phosphamide, fludarabine, alemtuzumab and rituximab
(CFAR) in 48 previously untreated patients with high-risk
features [9]. OR and CR were 94% and 69%, respectively,
with OR 77% and CR 54% in 13 patients with del
(17p13). Grade 3–4 neutropenia and thrombocytopenia
were observed in 71% and 42% of patients, respectively,
and 6% and 27% of patients developed major and minor
infections, respectively.
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Abstract 2091 updated results of a phase III study rand-
omizing 319 previously untreated patients to chloram-
bucil or bendamustine [10]. OR, CR and median PFS
favored bendamustine (67%, 32%, 21.5 months) over
chlorambucil (30%, 2%, 8.3 months), although benda-
mustine caused greater hematologic toxicity (40% vs.
19%), especially grade 3–4 neutropenia (23% vs. 9%).
Two studies of lenalidomide in previously untreated
patients were presented [11,12]. Abstract 44 summarized
results of a phase I study in 25 Canadian patients [11].
Due to grade 5 sepsis and grade 3–4 tumor lysis, the dose
was decreased from 25 mg to 2.5 mg and then escalated to
10 mg daily for 21 days every 28 days. Toxicity included
fatigue (78%), tumor flare (78%), rash (48%) and grade
3–4 neutropenia (43%). OR and CR were 65% and 0%,
respectively. Abstract 45 presented a study in 43 elderly
patients age 65 or older [12]. Lenalidomide was given
continuously, and 5–10 mg daily was the median deliv-
ered dose. Grade 3–4 myelosuppression and tumor flare
were observed in 26% and 44% of patients, respectively.
OR and CR were 54% and 0%, respectively. While lenal-
idomide is clearly active in CLL, the absence of CR in pre-
viously untreated patients was disappointing.
Abstract 47 presented a phase II study giving high dose
methylprednisolone 1000 mg/m2  day 1–3 every four
weeks and weekly rituximab (total dose 4500–6750 mg/
m2) to 28 patients [13]. OR and CR were 96% and 32%,
respectively. Patients were lesser splenomegaly and lower
beta-2-microglobulin levels were more likely to respond.
In the relapsed setting, abstract 329 presented final results
of the GCLLSG CLL2H study which administered subcu-
taneous alemtuzumab to 103 relapsed patients, many of
whom had high-risk features [14]. Infusion toxicity was
minimal, but grade 3–4 anemia (56%), thrombocytope-
nia (57%), anemia (49%), cytomegalovirus reactivation
(8%) and non-CMV infection (29%) were significant tox-
icities. Seventy-five patients died; 56% died of progressive
CLL, and 31% died of infection. OR (34%), CR (4%) and
median PFS (7.7 months) were similar to the results
achieved by intravenous alemtuzumab in the pivotal
CAM211 study [15].
Abstract 330 summarized a phase II GCLLSG trial admin-
istering bendamustine 70 mg/m2 on day 1–2 and rituxi-
mab 500 mg/m2 on day 1 to 81 relapsed CLL patients
[16]. OR and CR were 77% and 15%, respectively. Twelve
of 13 patients (92%) with del (11q22), 4/9 patients
(44%) with del (17p13), and 29/39 patients (74%)
responded, indicating that bendamustine is active in high-
risk relapsed CLL.
Abstract 46 presented combined phase I/II results of fla-
vopiridol (alvocidib) in 116 relapsed patients, 70% of
whom were fludarabine-refractory [17]. OR in this high-
risk population was 47%. Furthermore, 19/39 del
(17p13) patients (49%), 28/47 del (11q22) patients
(60%) and 22/52 complex karyotype patients (42%)
responded, demonstrating the activity of flavopiridol in
poor-risk groups with limited therapeutic options. Forty-
one of 85 patients (48%) with bulky lymphadenopathy >
5 cm responded. Median PFS in responders was 10–12
months across all risk groups. A registration study is ongo-
ing.
Finally, abstract 328 presented a pivotal phase II study of
the fully humanized anti-CD20 antibody ofatumumab
(HuMax-CD20) in relapsed patients refractory to both
fludarabine and alemtuzumab (DR, n = 59) or with bulky
lymphadenopathy refractory to fludarabine (BFR, n = 79)
[18]. OR, time to next therapy, and OS were similar for the
DR (51%, 9.0 months, 13.7 months) and BFR groups
(44%, 7.9 months, 15.4 months). These results have been
submitted for FDA approval.
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